Brief: Innate Pharma Announces IPH5201 Phase 2 Lung Cancer Study With AstraZeneca

Innate Pharma SA

03/06/2022 06:03

June 3 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA ANNOUNCES IPH5201 PHASE 2 STUDY IN LUNG
CANCER
    * ANTI-CD39 MONOCLONAL ANTIBODY IPH5201 ADVANCES TO PHASE 2
STUDY
IN LUNG CANCER
    * INNATE TO RECEIVE $5M MILESTONE PAYMENT FROM ASTRAZENECA
    * ASTRAZENECA AND INNATE WILL SHARE STUDY COSTS AND
ASTRAZENECA
WILL SUPPLY CLINICAL TRIAL DRUGS.
    * ASTRAZENECA CONDUCTED A PHASE 1 TRIAL IN SOLID TUMORS WITH
IPH5201 ALONE OR IN COMBINATION WITH DURVALUMAB (PD-L1)
    * PHASE 1 DATA ARE EXPECTED TO BE PRESENTED AT AN UPCOMING
MEDICAL
MEETING IN DUE COURSE.

Source text for Eikon:  ID:nBwhjgCa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)